Nishadil
Signup Signin
Delhi | 25°C (windy)
Lilly's Bold Bet: A Second Chance for a Troubled Gene Therapy in Retinal Disease

Lilly's Bold Bet: A Second Chance for a Troubled Gene Therapy in Retinal Disease
A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle

A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle
Ocular Therapeutix Soars Amid Frenzied Takeover Whispers: Is Amgen Eyeing a Biotech Gem?

Ocular Therapeutix Soars Amid Frenzied Takeover Whispers: Is Amgen Eyeing a Biotech Gem?
FDA Delivers Crushing Blow to Outlook Therapeutics: Eye Drug Approval for Wet AMD Declined

FDA Delivers Crushing Blow to Outlook Therapeutics: Eye Drug Approval for Wet AMD Declined
Load more..